Home/Filings/4/0001375151-20-000117
4//SEC Filing

FARR STEPHEN J 4

Accession 0001375151-20-000117

CIK 0001375151other

Filed

Jun 28, 8:00 PM ET

Accepted

Jun 29, 9:55 PM ET

Size

8.8 KB

Accession

0001375151-20-000117

Insider Transaction Report

Form 4
Period: 2020-06-25
FARR STEPHEN J
DirectorPresident and COO
Transactions
  • Exercise/Conversion

    Common Stock

    2020-06-25+27,50093,355 total
  • Exercise/Conversion

    Restricted Stock Units

    2020-06-2527,5000 total
    Common Stock (27,500 underlying)
  • Tax Payment

    Common Stock

    2020-06-25$28.12/sh13,635$383,41679,720 total
Footnotes (5)
  • [F1]The Restricted Stock Units (RSUs) were granted on March 14, 2017, with 100% of the RSUs to vest upon approval of the Company's New Drug Application (NDA) by the U.S. Food and Drug Administration for Fintepla. The NDA was approved on June 25, 2020.
  • [F2]Includes 604 shares acquired under the Company's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
  • [F3]Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of shares of RSUs described in footnote 1.
  • [F4]Each RSU represents a contingent right to receive one share of ZGNX common stock.
  • [F5]Not applicable.

Issuer

ZOGENIX, INC.

CIK 0001375151

Entity typeother

Related Parties

1
  • filerCIK 0001247666

Filing Metadata

Form type
4
Filed
Jun 28, 8:00 PM ET
Accepted
Jun 29, 9:55 PM ET
Size
8.8 KB